E2031
Eliprodil
≥98% (HPLC), powder
别名:
α-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol, SL 820715
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H23ClFNO
化学文摘社编号:
分子量:
347.85
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 5 mg/mL, clear
H2O: insoluble
创始人
Sanofi Aventis
储存温度
2-8°C
SMILES字符串
OC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3
InChI
1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
InChI key
GGUSQTSTQSHJAH-UHFFFAOYSA-N
基因信息
human ... GRIN2B(2904)
rat ... Adra1a(29412)
生化/生理作用
NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.
NR2B selective NMDA glutamate receptor antagonist.
特点和优势
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves
法规信息
新产品
此项目有
O A Dravolina et al.
Pharmacology, biochemistry, and behavior, 65(4), 611-620 (2000-04-15)
Current perspectives on the clinical use of NMDA receptor antagonists infer repeated administration schedules for the management of different pathological states. The development of tolerance and cross-tolerance between different NMDA receptor antagonists may be an important factor contributing to the
P Wlaź et al.
Neuropharmacology, 38(2), 243-251 (1999-04-28)
The discovery that glutamate's activity at the N-methyl-D-aspartate (NMDA) receptor is positively modulated by glycine and polyamines has led to a new pharmacological strategy that NMDA receptor-mediated events could be antagonized indirectly at the strychnine-insensitive glycine co-agonist site (glycine(B) receptor)
P J Missel et al.
Pharmaceutical development and technology, 11(1), 87-91 (2006-03-21)
Measurement of drug release of a sparingly soluble drug by conventional methods proceeds very slowly without the aid of surfactants. Two preliminary automated methods were developed that increase sensitivity and accelerate such studies by working at very small reservoir volumes.
N A Sharif et al.
The British journal of ophthalmology, 83(2), 236-240 (1999-07-09)
This study characterised the pharmacology of [3H]-ifenprodil binding to the polyamine binding sites (PBS) on the N-methyl-D-aspartate (NMDA) receptor channel complex on human retinas. These data were correlated with the known neuroprotective effects of ifenprodil and eliprodil. Specific binding of
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
J E Nash et al.
Experimental neurology, 155(1), 42-48 (1999-01-27)
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持